NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials

Strategies to reduce liver biopsy (LB) screen failures through better patient selection are needed for clinical trials. Standard fibrosis biomarkers were not derived to detect “at-risk” metabolic dysfunction-associated steatohepatitis (MASH; MASH with metabolic dysfunction-associated steatotic liver disease score ≥4 and fibrosis stage ≥2). We compared the performance of screening pathways that incorporate NIS2+™, an optimized version of the blood-based NIS4® te chnology designed to identify at-risk MASH, with those incorporating fibrosis (FIB)-4 within the RESOLVE-IT clinical trial (NCT02704403), aiming for optimized selection of patients for LB.

Source: Journal of Hepatology - December 5, 2023 Category: Gastroenterology Authors: Vlad Ratziu, Stephen A. Harrison, Yacine Hajji, Jeremy Magnanensi, Stephanie Petit, Zouher Majd, Elodie Delecroix, Christian Rosenquist, Dean Hum, Bart Staels, Quentin M. Anstee, Arun J. Sanyal Tags: Research Article Source Type: research